Gilead Sciences Inc
NASDAQ: GILD
$92.58
+$0.17 (+0.2%)
Closing Price on November 29, 2024
GILD Articles
As of the start of May of 2017, just 21 members of the S&P 500 Index were valued at less than 10 times expected earnings per share.
Published:
Last Updated:
The April 13 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
Published:
Last Updated:
With earnings starting to really snowball next week, and a market that seems to be teetering somewhat due to high valuations and some messy geopolitical issues, it makes sense for investors to look...
Published:
Last Updated:
The March 31 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
Published:
Last Updated:
A massive new Jefferies research report reminds investors that as a rule the first quarter is traditionally slower for biotechnology stocks.
Published:
Last Updated:
The health care sector in general has rallied since Trump took over the presidency, but now that his repeal of the ACA fell through, the health care rally is called into question.
Published:
Last Updated:
24/7 Wall St. has taken a look at a few companies within the health care sector that might have seen a reaction from the health care vote in Congress, or lack thereof.
Published:
Last Updated:
These are four top stocks to buy in a sector that has much more value than many on Wall Street. All are rated Buy at Jefferies and have outstanding upside potential.
Published:
Last Updated:
Gilead Sciences has long been in need of a catalyst to move its business, and a lot of investors and analysts alike have considered this company dead money until something happens.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday include AIG, Boeing, GameStop, Gilead Sciences, Starbucks, CIGNA, Ciena and Ferrari.
Published:
Last Updated:
The February 28 short interest data have been compared with the previous report, and short interest decreased in most of the selected biotech stocks.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday include American Express, Amgen, Encana, Gilead Science and Tesla.
Published:
Last Updated:
The February 15 short interest data have been compared with the previous report, and short interest increased in all the selected biotech stocks.
Published:
Last Updated:
These five top companies havehit some economic potholes but are primed for a comeback. They all are well known, make a variety of consumer and commercial products and will be around in the future.
Published:
Last Updated:
After Gilead Sciences reported fourth-quarter earnings on Tuesday, the stock hit a new multiyear low and analysts took the opportunity to slash their price targets.
Published:
Last Updated: